Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M. Schneeweiss A, et al. Among authors: marme f. Clin Breast Cancer. 2007 Apr;7(7):555-8. doi: 10.3816/CBC.2007.n.011. Clin Breast Cancer. 2007. PMID: 17509164 Clinical Trial.
Preeclampsia: increased expression of soluble ADAM 12.
Gack S, Marmé A, Marmé F, Wrobel G, Vonderstrass B, Bastert G, Lichter P, Angel P, Schorpp-Kistner M. Gack S, et al. Among authors: marme a, marme f. J Mol Med (Berl). 2005 Nov;83(11):887-96. doi: 10.1007/s00109-005-0714-9. Epub 2005 Oct 25. J Mol Med (Berl). 2005. PMID: 16247621
Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk.
Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Varon R, Schott S, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Müller H, Arndt V, Brenner H, Sohn C, Burwinkel B. Yang R, et al. Among authors: marme f. Breast Cancer Res Treat. 2011 Jun;127(2):549-54. doi: 10.1007/s10549-010-1244-x. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21046227
Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients.
Domschke C, Schuetz F, Ge Y, Rom J, Zorn M, Sinn HP, Marmé F, Schott S, Heil J, Scharf A, Sohn C, Schneeweiss A, Beckhove P. Domschke C, et al. Among authors: marme f. Cancer Immunol Immunother. 2011 Mar;60(3):401-11. doi: 10.1007/s00262-010-0956-4. Epub 2010 Dec 14. Cancer Immunol Immunother. 2011. PMID: 21161218 Free PMC article.
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, Mahner S, Ferschke I, Rom J, Sohn C, Schneeweiss A, Altevogt P. Marmé F, et al. Int J Cancer. 2012 Aug 15;131(4):E586-91. doi: 10.1002/ijc.27329. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22034009
Personalized therapy in breast cancer.
Marmé F, Schneeweiss A. Marmé F, et al. Onkologie. 2012;35 Suppl 1:28-33. doi: 10.1159/000334973. Epub 2012 Jan 20. Onkologie. 2012. PMID: 22286585 Free article.
The role of genetic breast cancer susceptibility variants as prognostic factors.
Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dörk T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olson JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John EM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G; kConFab Investigators; Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Pérez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK. Fasching PA, et al. Among authors: marme f. Hum Mol Genet. 2012 Sep 1;21(17):3926-39. doi: 10.1093/hmg/dds159. Epub 2012 Apr 24. Hum Mol Genet. 2012. PMID: 22532573 Free PMC article.
Predictors of resectability in breast-conserving therapy.
Rath MG, Heil J, Domschke C, Topic Z, Schneider S, Sinn HP, Marme F, Scharf A, Schneeweiss A, Sohn C, Rom J. Rath MG, et al. Among authors: marme f. Arch Gynecol Obstet. 2012 Oct;286(4):1023-31. doi: 10.1007/s00404-012-2401-8. Epub 2012 Jun 17. Arch Gynecol Obstet. 2012. PMID: 22707290
255 results